Clicky

Mersana Therapeutics, Inc.(MRSN)

Description: Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.


Keywords: Medicine Biotechnology Cancer Immunology Monoclonal Antibodies Chemotherapy Clinical Development Antibody Drug Conjugate Synaffix

Home Page: www.mersana.com

MRSN Technical Analysis

840 Memorial Drive
Cambridge, MA 02139
United States
Phone: 617 498 0020


Officers

Name Title
Ms. Anna Protopapas M.B.A. Pres, CEO & Director
Mr. Brian C. DeSchuytner Sr. VP & CFO
Dr. Timothy B. Lowinger Ph.D. Chief Science & Technology Officer
Ms. Alejandra Veronica Carvajal J.D. SVP, Sec. & Chief Legal Officer
Dr. Tushar Misra Ph.D. SVP & Chief Manufacturing Officer
Mr. Mikhail Papisov Ph.D. Co-Founder
Mr. Ashish Mandelia VP, Controller & Principal Accounting Officer
Mr. Jason Fredette Sr. VP of Investor Relations & Corp. Communications
Ms. Carla Poulson Chief People Officer
Mr. Chuck Miller Sr. VP of Regulatory Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 7.1434
Price-to-Sales TTM: 57.8327
IPO Date: 2017-06-28
Fiscal Year End: December
Full Time Employees: 169
Back to stocks